[Pharmacological strategies in prevention of vascular injury]

P Fernández Jiménez1, J Solera Santos

  • 1Servicio de Medicina Interna, Hospital General Universitario de Albacete, Spain. mpilarfj@sescam.jccm.es

Revista Clinica Espanola
|September 7, 2005
PubMed

Insights

Atherosclerosis, a leading cause of death, requires intensive management of risk factors, especially in diabetic patients. Early combination therapy in a single pill is recommended, pending further research.

Area of Science:

  • Cardiovascular Medicine
  • Endothelial Biology
  • Public Health

Context:

  • Atherosclerosis is a major global health concern, contributing significantly to morbidity and mortality worldwide.
  • The endothelial wall's injury is the primary pathophysiological basis of atherosclerosis.
  • Current medical trends emphasize aggressive management of cardiovascular risk factors.

Purpose:

  • To review key studies on atherosclerosis prevention and treatment.
  • To highlight the importance of addressing endothelial dysfunction.
  • To discuss contemporary therapeutic strategies and future research needs.

Summary:

  • This review synthesizes critical research on preventing and treating atherosclerosis, focusing on endothelial injury.
  • It advocates for intensive, combined interventions targeting cardiovascular risk factors, with a particular emphasis on diabetic individuals.
  • The trend favors earlier medical and pharmacological control, including single-pill combination therapies (e.g., statins, aspirin, ACE inhibitors).

Impact:

  • Promotes early and comprehensive management of atherosclerosis.
  • Highlights the potential of multi-component pharmacotherapy for cardiovascular risk reduction.
  • Identifies the need for robust prospective studies to validate combined therapeutic approaches.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...